IDEAS home Printed from https://ideas.repec.org/a/spr/stabio/v10y2018i1d10.1007_s12561-017-9204-1.html
   My bibliography  Save this article

Optimal Benchmark for Evaluating Drug-Combination Dose-Finding Clinical Trials

Author

Listed:
  • Beibei Guo

    (Louisiana State University)

  • Suyu Liu

    (The University of Texas MD Anderson Cancer Center)

Abstract

Numerous dose-finding methods have been proposed for drug-combination trials. A head-to-head comparison of the performance of these designs is difficult and often not very meaningful because different designs use different models and decision rules that often require judicious calibration to obtain good small-sample performance. It is desirable to have a general benchmark that can be used to evaluate the absolute performance of combination dose-finding designs. In this article, we propose an optimal nonparametric benchmark for evaluating drug-combination dose-finding methods, which provides an upper bound of accuracy beyond which further improvements are generally not achievable without making parametric assumptions of the dose-toxicity relationship. Our method is based on a new concept called critical information, which provides an upper bound on the information that we could possibly learn from patients while explicitly accounting for the partial order of the dose combinations, a fundamental feature of drug-combination trials. Our numerical study shows that the proposed benchmark provides a sharp upper bound that is useful for evaluating the performance of combination dose-finding designs.

Suggested Citation

  • Beibei Guo & Suyu Liu, 2018. "Optimal Benchmark for Evaluating Drug-Combination Dose-Finding Clinical Trials," Statistics in Biosciences, Springer;International Chinese Statistical Association, vol. 10(1), pages 184-201, April.
  • Handle: RePEc:spr:stabio:v:10:y:2018:i:1:d:10.1007_s12561-017-9204-1
    DOI: 10.1007/s12561-017-9204-1
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s12561-017-9204-1
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s12561-017-9204-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Nolan A. Wages & Mark R. Conaway & John O'Quigley, 2011. "Continual Reassessment Method for Partial Ordering," Biometrics, The International Biometric Society, vol. 67(4), pages 1555-1563, December.
    2. Guosheng Yin & Ying Yuan, 2009. "Bayesian dose finding in oncology for drug combinations by copula regression," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 58(2), pages 211-224, May.
    3. Kai Wang & Anastasia Ivanova, 2005. "Two-Dimensional Dose Finding in Discrete Dose Space," Biometrics, The International Biometric Society, vol. 61(1), pages 217-222, March.
    4. M.-K. Riviere & Y. Yuan & F. Dubois & S. Zohar, 2015. "A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 64(1), pages 215-229, January.
    5. Thomas M. Braun & Shufang Wang, 2010. "A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents," Biometrics, The International Biometric Society, vol. 66(3), pages 805-812, September.
    6. Mark R. Conaway & Stephanie Dunbar & Shyamal D. Peddada, 2004. "Designs for Single- or Multiple-Agent Phase I Trials," Biometrics, The International Biometric Society, vol. 60(3), pages 661-669, September.
    7. Ying Kuen Cheung, 2014. "Simple benchmark for complex dose finding studies," Biometrics, The International Biometric Society, vol. 70(2), pages 389-397, June.
    8. Peter F. Thall & Randall E. Millikan & Peter Mueller & Sang-Joon Lee, 2003. "Dose-Finding with Two Agents in Phase I Oncology Trials," Biometrics, The International Biometric Society, vol. 59(3), pages 487-496, September.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Chunyan Cai & Ying Yuan & Yuan Ji, 2014. "A Bayesian dose finding design for oncology clinical trials of combinational biological agents," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 63(1), pages 159-173, January.
    2. Márcio A. Diniz & Sungjin Kim & Mourad Tighiouart, 2020. "A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades," Stats, MDPI, vol. 3(3), pages 1-18, July.
    3. Beibei Guo & Elizabeth Garrett‐Mayer & Suyu Liu, 2021. "A Bayesian phase I/II design for cancer clinical trials combining an immunotherapeutic agent with a chemotherapeutic agent," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 70(5), pages 1210-1229, November.
    4. Nolan A. Wages & Mark R. Conaway & John O'Quigley, 2011. "Continual Reassessment Method for Partial Ordering," Biometrics, The International Biometric Society, vol. 67(4), pages 1555-1563, December.
    5. Guosheng Yin & Ying Yuan, 2009. "Bayesian dose finding in oncology for drug combinations by copula regression," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 58(2), pages 211-224, May.
    6. Xuelin Huang & Swati Biswas & Yasuhiro Oki & Jean-Pierre Issa & Donald A. Berry, 2007. "A Parallel Phase I/II Clinical Trial Design for Combination Therapies," Biometrics, The International Biometric Society, vol. 63(2), pages 429-436, June.
    7. Thomas M. Braun & Shufang Wang, 2010. "A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents," Biometrics, The International Biometric Society, vol. 66(3), pages 805-812, September.
    8. Guosheng Yin & Ying Yuan, 2009. "A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents," Biometrics, The International Biometric Society, vol. 65(3), pages 866-875, September.
    9. Koichi Hashizume & Jun Tshuchida & Takashi Sozu, 2022. "Flexible use of copula‐type model for dose‐finding in drug combination clinical trials," Biometrics, The International Biometric Society, vol. 78(4), pages 1651-1661, December.
    10. Mauro Gasparini & Stuart Bailey & Beat Neuenschwander, 2010. "Bayesian dose finding in oncology for drug combinations by copula regression," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 59(3), pages 543-544, May.
    11. Pavel Mozgunov & Rochelle Knight & Helen Barnett & Thomas Jaki, 2021. "Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study," IJERPH, MDPI, vol. 18(1), pages 1-19, January.
    12. Monia Ezzalfani, 2019. "How to design a dose-finding study on combined agents: Choice of design and development of R functions," PLOS ONE, Public Library of Science, vol. 14(11), pages 1-24, November.
    13. Sean M. Devlin & Alexia Iasonos & John O’Quigley, 2021. "Phase I clinical trials in adoptive T‐cell therapies," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 70(4), pages 815-834, August.
    14. Thomas M. Braun, 2018. "Motivating sample sizes in adaptive Phase I trials via Bayesian posterior credible intervals," Biometrics, The International Biometric Society, vol. 74(3), pages 1065-1071, September.
    15. Nadine Houede & Peter F. Thall & Hoang Nguyen & Xavier Paoletti & Andrew Kramar, 2010. "Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials," Biometrics, The International Biometric Society, vol. 66(2), pages 532-540, June.
    16. Hengzhen Huang & Hong†Bin Fang & Ming T. Tan, 2018. "Experimental design for multi†drug combination studies using signaling networks," Biometrics, The International Biometric Society, vol. 74(2), pages 538-547, June.
    17. Mark R. Conaway & Stephanie Dunbar & Shyamal D. Peddada, 2004. "Designs for Single- or Multiple-Agent Phase I Trials," Biometrics, The International Biometric Society, vol. 60(3), pages 661-669, September.
    18. B. Nebiyou Bekele & Yu Shen, 2005. "A Bayesian Approach to Jointly Modeling Toxicity and Biomarker Expression in a Phase I/II Dose-Finding Trial," Biometrics, The International Biometric Society, vol. 61(2), pages 343-354, June.
    19. Beibei Guo & Ying Yuan, 2017. "Bayesian Phase I/II Biomarker-Based Dose Finding for Precision Medicine With Molecularly Targeted Agents," Journal of the American Statistical Association, Taylor & Francis Journals, vol. 112(518), pages 508-520, April.
    20. Kai Wang & Anastasia Ivanova, 2005. "Two-Dimensional Dose Finding in Discrete Dose Space," Biometrics, The International Biometric Society, vol. 61(1), pages 217-222, March.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:stabio:v:10:y:2018:i:1:d:10.1007_s12561-017-9204-1. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.